Document is current
Any future updates will be listed below
-
Authors
Hall, Sara http://orcid.org/0000-0001-6585-9105
Orrù, Christina D.
Serrano, Geidy E.
Galasko, Douglas
Hughson, Andrew G.
Groveman, Bradley R.
Adler, Charles H.
Beach, Thomas G.
Caughey, Byron
Hansson, Oskar
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2016-00906)
Knut och Alice Wallenbergs Stiftelse (2017-0383)
Marianne and Marcus Wallenberg foundation (2015.0125)
Strategic Research Area MultiPark at Lund University
Alzheimerfonden (AF-939932)
Hjärnfonden (FO2021-0293)
Parkinsonfonden (1280/20)
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028)
Regionalt Forskningsstöd (2020-0314)
Swedish federal government under the ALF agreement (2018-Projekt0279)
National Institute of Neurological Disorders and Stroke (U24 NS072026)
National Institute on Aging (P30 AG19610, P30 AG072980)
Arizona Department of Health Services (contract 211002)
Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901, 1001)
Michael J. Fox Foundation for Parkinson's Research
Lund University
- License Information
-
More Information
Article History
Received: 26 May 2022
Accepted: 27 May 2022
First Online: 22 June 2022
Disclosures
: SH has no COIs. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from Amylyx, Alzpath, Biogen, Cerveau, Fujirebio, Genentech, Roche, and Siemens. BC, CDO, BRG, and AGH have patents pending that relate to various RT-QuIC assays. TGB has received consultancy fees from Vivid Genomics and Acadia Pharmaceuticals and TGB and GES have had research support from AVID Radiopharmaceuticals. CHA has received research support from the NIH, Michael J. Fox Foundation, and Arizona Biomedical Research Commission as well as consulting fees from Amneal, Avion, Cionic, CND Life Science, Eisai, Jazz, Neurocrine, and Precon Health. DG is supported by funding to the Shiley-Marcos ADRC at UC San Diego (NIH/NIA P30-AG062429). DG has served as a consultant for Biogen, Roche, General Electric Healthcare, Fujirebio, Amprion, Generian and Cognition Therapeutics.
